Drug Profile
IO 102
Alternative Names: IDOlong; IO-102Latest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator Herlev Hospital; IO Biotech
- Developer Herlev Hospital; IO Biotech; Merck & Co
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Malignant melanoma; Squamous cell cancer
- Phase I/II Non-small cell lung cancer
Most Recent Events
- 28 May 2023 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Denmark (SC)
- 12 Apr 2022 IO Biotech completes a phase I/II trial in Non-small cell lung cancer (Combination therapy, First-line therapy, Metastatic disease) in Germany, Spain, the Netherlands and United Kingdom (SC) (NCT03562871)
- 13 Jan 2021 IO Biotech plans a clinical trial in Malignant melanoma (Combination therapy; Metastatic disease)